Drugs / Elinogrel
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00984113 | Sep → Dec 2009 | impaired renal function disease | Portola Pharmaceuticals | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00751231 | Dec 2008 → Apr 2010 | — | Portola Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00546260 | Nov 2007 → Jul 2008 | myocardial infarction | Alexion Pharmaceuticals, Inc. | Terminated | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | elinogrel | “Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous...” PMID 19958867 ↗ Dec 2009 |
| Known as | ELINOGREL POTASSIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103828 ↗ |
| Known as | Elinogrel potassium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103828 ↗ |
| Known as | PRT-060128 POTASSIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103828 ↗ |
| Known as | PRT060128 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00751231 ↗ |
| Action | Inhibit | “a competitive, reversible intravenous and oral P2Y(12) inhibitor” PMID 22647518 ↗ May 20121“Purinergic receptor P2Y12 antagonist” CHEMBL2103828 ↗ |
| Modality | Small molecule | — CHEMBL2103828 ↗ |
| Route | Intravenous | “elinogrel administered as a single intravenous bolus” PMID 19958867 ↗ Dec 2009 |
| Target | P2RY12 | “Purinergic receptor P2Y12 antagonist” CHEMBL2103828 ↗ |